Aura Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
AURA$7.65-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Year EndedDecember 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating Expenses: | ||
| Research and development | $90,300 | $73,302 |
| General and administrative | 22,491 | 22,814 |
| Total operating expenses | 112,791 | 96,116 |
| Total operating loss | (112,791) | (96,116) |
| Other income (expense): | ||
| Interest income, including amortization and accretion income | 6,631 | 9,429 |
| Other income (expense) | 77 | (120) |
| Total other income | 6,708 | 9,309 |
| Loss before income taxes | (106,083) | (86,807) |
| Income tax provision, net | (108) | (112) |
| Net loss | (106,191) | (86,919) |
| Net loss per common share—basic and diluted | (1.76) | (1.75) |
| Weighted average common stock outstanding—basic and diluted | 60,337,608 | 49,650,480 |
| Comprehensive loss: | ||
| Net loss | $(106,191) | $(86,919) |
| Other comprehensive items: | ||
| Unrealized loss on marketable securities | (179) | (271) |
| Currency translation adjustment | (186) | (5) |
| Total other comprehensive loss | (365) | (276) |
| Total comprehensive loss | $(106,556) | $(87,195) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.